>

Amit Sachdev - Vertex Pharmaceuticals President

<div class='circular--portrait' style='background:#754DEB;color: white;font-size:3em;padding-top: 40px;;'>VRT</div>
VRTX -- USA Stock  

Fiscal Quarter End: March 31, 2020  

  President
Mr. Amit K. Sachdev, J.D., is Executive Vice President, Chief Regulatory Officer and Chief of Staff to the CEO of the Vertex Pharmaceuticals Incorporated. He served as our Executive Vice President, Policy, Access and Value, from October 2014 through December 2016. In 2007, he joined us as a Senior Vice President, and has led our government affairs and public policy activities, as well as our patient advocacy programs. From 2010 through 2013 he established our first international commercial operations in Canada. Prior to joining us, Mr. Sachdev served as Executive Vice President, Health of the Biotechnology Industry Organization and was the Deputy Commissioner for Policy at the FDA, where he also served in several other senior positions. Prior to the FDA, Mr. Sachdev served as Majority Counsel to the Committee on Energy and Commerce in the United States House of Representatives and practiced law at the Chemical Manufacturers Association, and subsequently at the law firm of Ropes Gray LLP
Age: 50  President Since 2017      
617 341-6100  www.vrtx.com
Sachdev holds a B.S from Carnegie Mellon University, and a J.D. from Emory University School of Law.

Amit Sachdev Latest Insider Activity

Management Efficiency

The company currently holds 649.8 M in liabilities with Debt to Equity (D/E) ratio of 12.3 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Vertex Pharmaceuticals has Current Ratio of 3.37 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives

PRESIDENT Since

Grainne QuinnPerrigo Company Plc
2016
Heidi ChenZoetis
2012
James DillardPerrigo Company Plc
2019
Cartikeya ReddyDr Reddys Laboratories Ltd
2016
Jeffrey NeedhamPerrigo Company Plc
2009
Amit BiswasDr Reddys Laboratories Ltd
2016
Christopher FenimoreRegeneron Pharmaceuticals
2017
Samiran DasDr Reddys Laboratories Ltd
2016
Jay MarkowitzRegeneron Pharmaceuticals
2017
Scott JamisonPerrigo Company Plc
2011
Ronald JanishPerrigo Company Plc
2015
K RaoDr Reddys Laboratories Ltd
2016
J RamachandranDr Reddys Laboratories Ltd
2016
Svend AndersenPerrigo Company Plc
2017
Alejandro BernalZoetis
2015
Michael StewartPerrigo Company Plc
2004
Michael AbermanRegeneron Pharmaceuticals
2015
Douglas BoothePerrigo Company Plc
2013
Alok SonigDr Reddys Laboratories Ltd
2015
Roman TrawickiZoetis
2015
Marion McCourtRegeneron Pharmaceuticals
2018

Company Summary

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for the treatment of cystic fibrosis . The company was founded in 1989 and is headquartered in Boston, Massachusetts. Vertex Pharmaceuticals operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 3000 people.Vertex Pharmaceuticals Incorpor (VRTX) is traded on BATS Exchange in USA and employs 3,000 people.

Vertex Pharmaceuticals Leadership Team

William Young, Independent DirectorView
Reshma Kewalramani, Executive Vice President - Global Medicines Development and Medical Affairs and Chief Medical OfficerView
Michael Parini, Executive Vice President and Chief Legal OfficerView
Alan Garber, Independent DirectorView
Joshua Boger, Executive Director and Chairman of Science and Technology CommitteeView
John Gray, Senior Vice President Genetic TherapiesView
Margaret McGlynn, Independent DirectorView
Sangeeta Bhatia, DirectorView
Terrence Kearney, Independent DirectorView
Ian Smith, CFO, Executive Vice PresidentView
Paul Silva, Senior Vice President Corporate ControllerView
David Altshuler, Independent DirectorView
Jeffrey Chodakewitz, Chief Medical Officer and Senior Vice President - Global Medicines DevelopmentView
Elaine Ullian, Co-Lead Independent DirectorView
Amit Sachdev, Senior Vice President - Global Government Strategy, Market Access and ValueView
David Greenway, DirectorView
Charles Wagner, CFO, Executive Vice PresidentView
Bruce Sachs, Co-Lead Independent DirectorView
Lloyd Carney, Independent DirectorView
Michael Partridge, Vice President - Investor RelationsView
Yuchun Lee, Independent DirectorView
Kimberly White, Senior Vice President and Chief Communications OfficerView
Stuart Arbuckle, Chief Commercial Officer and Executive VPView
Thomas Graney, CFO, Senior Vice PresidentView
Charles Milstein, Executive Vice President Chief Legal and Administrative OfficerView
Jeffrey Leiden, Chairman of the Board and Presidentident, CEOView

Stock Performance Indicators

Current Sentiment - VRTX

Vertex Pharmaceuticals Investor Sentiment

Most of Macroaxis users are at this time bullish on Vertex Pharmaceuticals Incorpor. What is your outlook on investing in Vertex Pharmaceuticals Incorpor? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Also Currentnly Active

Purchased over 90 shares of
a day ago
Traded for 5.02
Purchased over 90 shares of
a day ago
Traded for 28.3
Purchased over 90 shares of
a day ago
Traded for 10.58
Also please take a look at World Market Map. Please also try Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.